Page 8 - தகவல்கள் பாதுகாப்பு கண்காணிப்பு பலகை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Ninety Day Survival Outcomes in COVID-19 ARDS Trial of Remestemcel-L Presented at ISCT Meeting . Mesoblast LimitedJuly 19, 2021 GMT NEW YORK, July 18, 2021 (GLOBE NEWSWIRE) Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, presented 90-day survival outcomes from the 222-patient randomized controlled trial of remestemcel-L in ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS) at an invited presentation on July 17 to the International Society for Cell & Gene Therapy (ISCT) Scientific Signatures Series on Cell and Gene Therapies in Lung Diseases and Critical Illnesses. The results showed that two doses of remestemcel-L at days 3-5 conferred durable survival benefit through at least 90 days in the pre-specified subgroup of patients under age 65.

United statesKristen bothwellPaul hughesDrug administrationAustralian securities exchangeCorporate communications investorsMesoblast limited nasdaqInternational society for cell gene therapyInternational societyGene therapyScientific signatures seriesGene therapiesLung diseasesHazard ratioAcute respiratory distress syndromeData safety monitoring board